Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURANEST vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Induction of general anesthesia,Supplementation of subpotent anesthetic agents (off-label),Procedural sedation (off-label)
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Primarily hepatic via hydrolysis by esterases (plasma and hepatic) to inactive metabolites. Less than 5% excreted unchanged in urine.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
85-90% bound primarily to alpha-1-acid glycoprotein; minor binding to albumin.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Vd is 2.5-3.5 L/kg, indicating extensive extravascular distribution and tissue binding.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Oral: 60-70% (first-pass metabolism); Intramuscular: ~90%; Intravenous: 100%.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No specific guidelines; contraindicated in severe renal impairment due to potential for accumulation of preservatives.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
Use with caution; no specific Child-Pugh adjustments available. Contraindicated in severe hepatic disease due to impaired metabolism.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Not recommended for pediatric use due to limited data and high risk of neurotoxicity.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Reduce dose and volume; monitor for prolonged motor block and hypotension. Use lowest effective dose.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
None.
Not available.
Adrenocortical suppression: Etonidate inhibits 11β-hydroxylase, reducing cortisol and aldosterone synthesis; may last up to 24 hours after single dose.,Myoclonus: Involuntary muscle movements occur in up to 70% of patients, especially with rapid injection.,Hypotension: Less pronounced than with other induction agents, but may occur, particularly in hypovolemic patients.,Injection site pain: Common with peripheral administration.,Use in intensive care: Prolonged infusion associated with increased mortality; not recommended for sedation in ICU.,Pregnancy category C: Use only if clearly needed.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to etonidate or any component of the formulation,Use as sole anesthetic agent for major surgery without adequate muscle relaxation or intubation,Acute porphyria (relative contraindication)
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No known direct food interactions. However, avoid hot beverages and foods until numbness resolves to prevent oral burns. No specific dietary restrictions.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only if clearly needed. Second and third trimesters: no known teratogenic risk; may cause fetal bradycardia if high systemic levels occur. Avoid in near-term unless necessary due to neonatal effects.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Excreted in breast milk in low concentrations; M/P ratio not established. Expected milk levels are minimal after regional anesthesia. Use with caution; monitor infant for signs of local anesthetic toxicity (irritability, drowsiness). Instruct mother to discard milk for 4 hours after injection if concerned.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
No standard dose adjustments required for pregnancy per se. However, due to increased epidural venous plexus engorgement and decreased volume of distribution in the epidural space, reduce dose by 20-30% for epidural anesthesia to avoid unintended high block. Use lowest effective dose to minimize maternal and fetal exposure.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
DURANEST (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) is an amide local anesthetic commonly used in dentistry. Not effective for topical anesthesia; must be injected. Onset is rapid (1-3 min) with duration of pulpal anesthesia ~60-75 min and soft tissue anesthesia ~2-4 h. Maximum dose: 7 mg/kg (epinephrine 1:100,000) or 5 mg/kg (epinephrine 1:200,000). Avoid in patients with sulfite allergy (epinephrine component) or para-aminobenzoic acid (PABA) hypersensitivity. Caution in patients with methemoglobinemia (can cause methemoglobin formation at high doses).
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Avoid eating or drinking until numbness in mouth and throat has fully resolved (usually 2-4 hours) to prevent accidental biting or burns.,Do not chew gum or eat hard foods while numb.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or prolonged numbness (>8 hours) to your dentist immediately.,Inform your dentist of all medications you are taking, especially MAO inhibitors, tricyclic antidepressants, beta-blockers, and anticoagulants.,If you have a history of sulfite sensitivity, tell your dentist before the procedure.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURANEST vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
DURANEST is a Local Anesthetic that works by Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURANEST and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURANEST is: 2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURANEST and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURANEST is classified as Category C. Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only i. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.